Physiology and Pharmacology of BRS-3 (Bombesin Receptor Subtype-3)

BRS-3（铃蟾肽受体亚型 3）的生理学和药理学

• 批准号: 8349965
• 负责人: MARC L REITMAN
• 金额: $ 91.61万
• 依托单位: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8349965
• 关键词: Ablation; Affinity; Agonist; Area; Beta Cell; Blood Pressure; Body Temperature; Body Weight; Bombesin; Bombesin Receptor; Brain; Brain Stem; Cannabinoids; Cardiovascular Diseases; Cell Line; Cell Nucleus; Cholelithiasis; Comorbidity; Degenerative polyarthritis; Drug Kinetics; Dyslipidemias; Eating; Effectiveness; Fasting; G-Protein-Coupled Receptors; Genetic; Glucose; Goals; Health; Homeostasis; Hypertension; Hypothalamic structure; Islets of Langerhans; Knock-out; Knockout Mice; Laboratories; Laboratory Research; Leptin; Life Expectancy; Ligands; Malignant Neoplasms; Measures; Metabolic; Midbrain structure; Monitor; Mus; Names; National Institute of Diabetes and Digestive and Kidney Diseases; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Pharmacology; Physiology; Process; Publications; Regulation; Reproductive Behavior; Research; Risk; Rodent; Role; Signal Pathway; System; Telemetry; Transgenic Mice; United States National Institutes of Health; Work; attenuation; bombesin receptor subtype 3; complement pathway; improved; insulin secretion; interest; member; neuropeptide Y; obesity treatment; recombinase

I arrived at the NIH during this year and much of my effort has been devoted to setting up my laboratory. We have established a colony of BRS-3 knockout mice. A conditional floxed knockout does not yet exist for BRS-3 and we are in the process of making such a mouse. We also plan to generate a transgenic mouse with Cre recombinase driven by BRS-3. An MTA that enables us to get BRS-3 compounds (MK-5046, MK-7255, and Bantag-1) from Merck has been created. The mouse physiology capabilities needed are also being established, including the ability to measure metabolic rate at thermoneutrality and a telemetry system for continuous body temperature monitoring. Additionally, work on BRS-3 that I was involved with at Merck Research Laboratories prior to my arrival at NIDDK continues to be guided through the publication process.

我在这一年来到了NIH，我的大部分精力都花在了建立我的实验室上。 我们建立了一个BRS-3基因敲除小鼠的群体。 BRS-3的条件性floxed敲除还不存在，我们正在制造这样的小鼠。 我们还计划用BRS-3驱动的Cre重组酶产生转基因小鼠。 已经创建了MTA，使我们能够从默克获得BRS-3化合物（MK-5046、MK-7255和Bantag-1）。 还正在建立所需的小鼠生理学能力，包括在热中性下测量代谢率的能力和用于连续体温监测的遥测系统。 此外，在我到达NIDDK之前，我在默克研究实验室参与的BRS-3工作继续在出版过程中得到指导。